Page last updated: 2024-08-21

azomycin and pa 824

azomycin has been researched along with pa 824 in 178 studies

Research

Studies (178)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's31 (17.42)29.6817
2010's97 (54.49)24.3611
2020's50 (28.09)2.80

Authors

AuthorsStudies
Anderson, SW; Arain, TM; Baker, WR; Barry, CE; Kreiswirth, BN; Langhorne, MH; McMurray, DN; Sherman, DR; Stover, CK; Towell, JA; VanDevanter, DR; Warrener, P; Yuan, Y1
Bae, YM; Bair, TB; Choi, KP; Daniels, L1
Choi, KP; Daniels, L; Kendrick, N1
Doi, N1
Bishai, W; Grosset, J; Lounis, N; Nuermberger, E; Rosenthal, I; Tyagi, S; Williams, K; Yoshimatsu, T1
Driscoll, DK; Gruppo, V; Johnson, CM; Lenaerts, AJ; Marietta, KS; Orme, IM; Reynolds, RC; Rose, JD; Tompkins, NM1
Ahmad, K1
Albert, TJ; Barry, CE; Boshoff, H; Daniels, L; Dick, T; Dowd, CS; Manjunatha, UH; Norton, JE; Pang, SS; Zhang, L1
Andries, K; Chauffour, A; Jarlier, V; Ji, B1
Chauffour, A; Jarlier, V; Ji, B; Lefrançois, S; Robert, J; Truffot, C1
Almeida, D; Bishai, WR; Grosset, JH; Nuermberger, E; Peloquin, CA; Rosenthal, I; Tyagi, S; Williams, KN1
Barry, CE; Dowd, CS; Krahenbuhl, JL; Lahiri, R; Manjunatha, UH; Randhawa, B1
Bloomer, WD; McNeil, MR; Papadopoulou, MV1
Zhang, Y1
Coates, AR; Hu, Y; Mitchison, DA1
Almeida, D; Grosset, JH; Nuermberger, E; Rosenthal, I; Tasneen, R; Tyagi, S; Williams, KN1
Barry, CE; Dowd, CS; Goodwin, MB; Keller, TH; Knox, JE; Li, X; Lipinski, CA; Manjunatha, UH1
Baker, EN; Bashiri, G; Moreland, NJ; Squire, CJ1
Nau, JY1
Anderson, RF; Boyd, M; Denny, WA; Maroz, A; Palmer, BD; Shinde, SS1
Mancera, RL; Rivers, EC1
Grosset, J; Nuermberger, E; Tasneen, R; Tyagi, S; Williams, K1
Nathan, C1
Barry, CE; Boshoff, HI; Dowd, CS; Ha, YH; Jiricek, J; Kang, S; Keller, TH; Kim, P; Ledwidge, R; Lee, IY; Manjunatha, U; Niyomrattanakit, P; Singh, R; Zhang, L1
Anderson, RF; Blaser, A; Denny, WA; Franzblau, SG; Ma, Z; Palmer, BD; Shinde, SS; Thompson, AM1
Edwards, DA; Elbert, KJ; Garcia-Contreras, L; Hickey, AJ; Peloquin, CA; Sung, JC; Verberkmoes, JL1
Ginsberg, AM; Laurenzi, MW; Rouse, DJ; Spigelman, MK; Whitney, KD2
Blaser, A; Denny, WA; Franzblau, SG; Kmentova, I; Ma, Z; Palmer, BD; Sutherland, HS; Thompson, AM; Wan, B; Wang, Y5
Anderson, RF; Denny, WA; Franzblau, SG; Ma, Z; Maroz, A; Palmer, BD; Shinde, SS1
Edwards, DA; Elbert, KJ; Garcia-Contreras, L; Hickey, AJ; Muttil, P; Padilla, D; Sung, JC; Telko, M; Verberkmoes, JL1
Dawson, R; Diacon, AH; Donald, PR; Ginsberg, AM; Hanekom, M; Laurenzi, MW; Maritz, SJ; Narunsky, K; Rouse, DJ; Spigelman, MK; van Niekerk, C; Venter, A; Whitney, K1
Cole, ST; Dhar, N; Ha, YH; Hartkoorn, RC; Sala, C; Schneider, P; Zhang, M1
Marsini, MA; Reider, PJ; Sorensen, EJ1
Ahmad, Z; Derendorf, H; Ginsberg, A; Grosset, JH; Nuermberger, EL; Peloquin, CA; Singh, RP; Tyagi, S1
Anderson, RF; Baker, EN; Bashiri, G; Denny, WA; Dogra, M; Helsby, NA; O'Toole, R; Palmer, BD; Shinde, SS; Tingle, MD1
Hutson, S1
Barry, CE; Bollo, S; Boshoff, HI; Dowd, CS; Kang, S; Núñez-Vergara, LJ; Squella, JA; Zhang, L1
Denny, WA; Palmer, BD1
Degani, MS; Tawari, NR1
Barry, CE; Boshoff, HI; Cherian, J; Choi, I; Dartois, V; Dick, T; Goodwin, M; Ha, YH; Jiricek, J; Keller, TH; Lakshminarayana, SB; Lee, YS; Manjunatha, UH; Mukherjee, T; Nayyar, A; Niyomrattanakit, P; Ravindran, S; Singh, R1
Ginsberg, A1
Cui, Z; Fu, X; Hu, Z; Jin, K; Li, Y; Wu, W; Yu, G; Zhang, L1
Archer, JA; Baù, D; Feuerriegel, S; Köser, CU; Marti-Renom, MA; Niemann, S; Rüsch-Gerdes, S; Summers, DK1
Andries, K; Li, SY; Mdluli, KE; Nuermberger, EL; Peloquin, CA; Tasneen, R; Taylor, D; Williams, KN1
Barry, CE; Boshoff, HI; Cherian, J; Dick, T; Dowd, CS; Gurumurthy, M; Lee, YS; Manjunatha, UH; Mukherjee, T; Nayyar, A; Niyomrattanakit, P; Singh, R; Tay, JA1
Bishai, WR; Davis, SL; Harper, J; Jain, SK; Kramnik, I; Nuermberger, EL; Pomper, MG; Skerry, C; Tasneen, R; Weir, M1
Campbell, S; Jakubiec, W; Ladutko, L; Miller, PF; Mitton-Fry, M; Paige, D; Silvia, A; Wallis, RS1
Becker, P; Dawson, R; Diacon, AH; Donald, PR; du Bois, J; Erondu, N; Ginsberg, AM; Narunsky, K; Spigelman, MK; van Niekerk, C; Venter, A1
Roehr, B1
Amoabeng, O; Andries, K; Mdluli, KE; Minkowski, A; Nuermberger, EL; Peloquin, CA; Taylor, D; Wallis, RS; Williams, K1
Campos-Rivera, MP; Cole, ST; Gonzalez-Martinez, NA; Ocampo-Candiani, J; Vera-Cabrera, L1
Becker, P; Dawson, R; Diacon, AH; Donald, PR; Everitt, D; Mendel, CM; Spigelman, MK; Symons, G; van Niekerk, C; Venter, A; von Groote-Bidlingmaier, F; Winter, H1
Kmietowicz, Z1
Cole, ST; Hartkoorn, RC; Lechartier, B1
Dawson, R; Diacon, A1
Egizi, E; Erondu, N; Everitt, D; Ginsberg, A; Pauli, E; Rouse, DJ; Severynse-Stevens, D; Winter, H1
Alsultan, A; Belchis, DA; Dutta, NK; Gniadek, TJ; Karakousis, PC; Mdluli, KE; Nuermberger, EL; Peloquin, CA; Pinn, ML1
Egizi, E; Erondu, N; Everitt, D; Ginsberg, A; Pauli, E; Whitney, K; Winter, H1
Anand, RS; Paramasivan, CN; Somasundaram, S; Venkatesan, P1
Mukhopadhyay, B; Purwantini, E1
Jeong, BH; Koh, WJ; Kwon, YS1
Garcia-Prats, AJ; Hesseling, AC; Schaaf, HS; Seddon, JA1
Diao, C; Liang, L; Liu, X; Wang, L; Xu, Y; Zhang, J; Zhang, S1
Allen, R; Aweeka, F; Bao, J; Cramer, Y; Dooley, KE; Haas, DW; Koletar, SL; Luetkemeyer, AF; Marzan, F; Murray, S; Park, JG; Savic, R; Sutherland, D1
Barry, CE; Blasco, F; Boshoff, HI; Cherian, J; Dick, T; Goh, A; Gurumurthy, M; Ho, PC; Jiricek, J; Lakshminarayana, SB; Manjunatha, UH; Nanjundappa, M; Nayyar, A; Ravindran, S; Singh, R1
Dutta, NK; Karakousis, PC1
Cho, S; Franzblau, SG; Kim, Y; Lu, Y; Ma, Z; Mdluli, K; Upton, AM; Wang, B; Wang, Y; Xu, J; Yang, TJ1
Amoabeng, O; Mdluli, KE; Minkowski, A; Nuermberger, EL; Tasneen, R; Upton, AM; Williams, K1
Chang, KC; Heyckendorf, J; Lange, C; Olaru, ID; von Groote-Bidlingmaier, F; Yew, WW1
Burger, DA; Dawson, R; Diacon, AH; Donald, PR; Everitt, D; Hutchings, J; Mendel, CM; Schall, R; Symons, G; van Niekerk, C; Venter, A; von Groote-Bidlingmaier, F1
Gund, MG; Mangu, NK; Nair, V; Okello, MO; Seo, BI1
Burger, DA; Conradie, A; Dawson, R; Diacon, AH; Donald, PR; Eisenach, K; Everitt, D; Ive, P; Mendel, CM; Ntinginya, NE; Page-Shipp, L; Pym, A; Reither, K; Schall, R; Spigelman, M; van Niekerk, C; Variava, E; Venter, A; von Groote-Bidlingmaier, F1
Migliori, GB; Sotgiu, G1
A Bester, L; Bratkowska, D; Govender, T; Kruger, HG; Maguire, GE; Shobo, A; Singh, S1
Inturi, B; Pujar, GV; Purohit, MN1
Bifani, P; Chua, A; Ghode, P; Haver, HL; Lakshminarayana, SB; Mathema, B; Singhal, A; Wintjens, R1
Arora, G; Kang, YG; Lee, IY; Park, CY; Shin, H; Singh, R; Yu, CM1
Baijnath, S; Bester, LA; Bratkowska, D; Govender, T; Kruger, HG; Naicker, T; Naiker, S; Shobo, A; Singh, SD; Somboro, AM1
Ballinger, E; Glasheen, J; Gold, B; Ling, Y; Nathan, C; Quezada, LL; Roberts, J; Somersan-Karakaya, S; Warren, JD; Warrier, T1
Franzblau, SG; Gutka, HJ; Movahedzadeh, F; Wang, Y1
Betoudji, F; Converse, PJ; Dartois, V; Li, SY; Mdluli, KE; Mendel, CM; Nuermberger, EL; Tasneen, R; Tyagi, S; Williams, K; Yang, T1
Duan, H; Liang, L; Liu, X; Ma, Y; Wang, L; Wang, Q; Yao, J; Zhang, R; Zhang, S; Zhou, X1
Bruhn, DF; Lee, RE; Lenaerts, AJ; Liu, J; Scherman, MS; Singh, AP; Yang, L1
Das, SC; Krittaphol, W; Momin, MAM; Thien, SJ1
Koniordou, M; Patterson, S; Seifert, K; Wyllie, S1
Cohen, J1
Mendel, C; Murray, S; Spigelman, M1
Anderson, RF; Blaser, A; Chatelain, E; Denny, WA; Franzblau, SG; Launay, D; Ma, Z; Maes, L; Palmer, BD; Shinde, SS; Thompson, AM; Wan, B; Wang, Y1
Ahmed, Z; Bhagat, A; Kour, G; Singh, PP1
Converse, PJ; Li, SY; Mdluli, K; Nuermberger, EL; Soni, H; Tasneen, R; Tyagi, S1
Li, DG; Ren, ZX1
Alland, D; Bajaj, A; Dhiman, R; Gosain, TP; Hwang, YK; Jung, MG; Kidwai, S; Kumar, P; Kumar, S; Lee, IY; Mawatwal, S; Park, CY; Singh, R; Song, CS; Tiwari, P1
Bacchi, CJ; Braillard, S; Chatelain, E; Denny, WA; Gaukel, E; Launay, D; Maes, L; Marshall, AJ; Mowbray, CE; Thompson, AM; Wring, SA; Yarlett, N1
Connell, N; Dartois, V; Freundlich, JS; Ho, HP; Inoyama, D; Kandasamy, S; Kumar, P; Occi, J; Paget, SD; Perryman, AL; Russo, R; Singleton, E; Tuckman, M; Zimmerman, MD1
Feng, T; Jing, J; Liu, X; Mi, L; Shen, X; Wang, L; Zhang, R; Zhang, S; Zhao, J; Zhou, N1
Aguilar-Ayala, DA; Cnockaert, M; Gonzalez-Y-Merchand, J; Martin, A; Palomino, JC; Vandamme, P1
Bujalska-Zadrozny, M; Pstragowski, M; Zbrzezna, M1
Baillie, L; Baptista, R; Beckmann, M; Fazakerley, DM; Mur, LAJ1
Lyons, MA3
Baijnath, S; Govender, T; Kruger, HG; Makatini, MM; Naicker, T; Pamreddy, A; Shobo, A1
Arbex, MA; D'Ambrosio, L; Dalcolmo, M; Duarte, R; Gaga, M; Migliori, GB; Munoz-Torrico, M; Rendon, A; Silva, DR; Tiberi, S; Visca, D; Zumla, A1
Loganathan, U; Mukhopadhyay, B; Purwantini, E1
Chaudhari, HK; Pahelkar, A1
Borkute, R; Choudhari, AS; Degani, MS; Krishna, VS; Mali, HM; Sabale, SS; Sarkar, D; Sriram, D1
de Miranda Silva, C; Drusano, GL; Hajihosseini, A; Louie, A; Myrick, J; Nole, J; Schmidt, S1
Ang, CW; Avery, VM; Blaskovich, MAT; Butler, MS; Cooper, MA; Debnath, A; Hahn, HJ; Jarrad, AM; Jones, AJ; Karoli, T; Pelingon, R; Sykes, ML; Tan, L; West, NP; Woods, K1
Laughon, BE; Lee, SFK; Lipman, M; McHugh, TD1
Chu, N; Huang, H; Jing, W; Pang, Y; Shang, Y; Wang, F; Wen, S; Xue, Y; Zhang, T; Zong, Z1
Fattorini, L; Giannoni, F; Iacobino, A; Pardini, M; Piccaro, G1
Del Parigi, A; Everitt, D; Li, H; Li, M; Mendel, C; Nedelman, JR; Salinger, DH1
Billard, T; Dickson, C; Gampe, CM; Ghiazza, C; Tlili, A1
Ceyssens, PJ; Coppee, JY; Legendre, R; Mathys, V; Sismeiro, O; Sury, A; Van den Bossche, A; Varet, H1
Everitt, D; Nedelman, JR; Salinger, DH; Subramoney, V1
Dheda, K; Dooley, KE; Furin, J; Gumbo, T; Maartens, G; Murray, M; Nardell, EA; Warren, RM1
Cook-Scalise, S; Denkinger, CM; Dowdy, DW; Kendall, EA; Malhotra, S1
Burki, T1
Keam, SJ1
Mushtaq, A1
Bendet, P; Berg, A; Cirrincione, K; Deshpande, D; Gumbo, T; Hanna, D; Hermann, D; Magombedze, G; Martin, K; Romero, K; Srivastava, S; van Zyl, J1
Burger, DA; Conradie, A; Conradie, F; Crook, AM; Dawson, R; Diacon, AH; Everitt, DE; Haraka, F; Li, M; Mendel, CM; Ntinginya, NE; Okwera, A; Rassool, MS; Reither, K; Sebe, MA; Spigelman, M; Staples, S; Tweed, CD; van Niekerk, CH; Variava, E1
Furin, J; McKenna, L1
Aher, RB; Sarkar, D1
Afriat-Jurnou, L; Ahmed, FH; Almeida, DV; Aung, HL; Beatson, SA; Cook, GM; Forde, BM; Greening, C; Hards, K; Harold, LK; Jackson, CJ; Lee, BM; Mohamed, AE; Nuermberger, EL; Pidot, SJ; Stinear, TP; Taylor, MC; West, NP1
de Jong, BC; Decroo, T; Lynen, L; Piubello, A; Van Deun, A1
Bateson, A; Conradie, F; Crook, AM; Diacon, AH; Egizi, E; Everitt, D; Howell, P; Hunt, R; Li, M; McHugh, TD; Mendel, CM; Moreira, J; Ngubane, N; Olugbosi, M; Spigelman, M; Timm, J; Van Niekerk, C; Wills, GH1
Farhat, M; Kadura, S; King, N; Köser, CU; Nakhoul, M; Theron, G; Zhu, H1
Bigelow, KM; Chang, YS; Dooley, KE; Nuermberger, EL; Tasneen, R1
Hussar, DA1
Bashiri, G; Ioerger, T; Lanoix, JP; Lee, J; Li, SY; Nuermberger, E; Rifat, D; Sacchettini, J; Shah, K1
Everitt, D; Li, M; Mendel, CM; Nedelman, JR; Salinger, DH; Spigelman, M; Subramoney, V; Wade, K; Woolson, R1
Chopra, S; Dasgupta, A; Thakare, R1
El-Amin, W; Everitt, D; Li, M; Makhene, MK; Nedelman, J; Osborn, B; Saviolakis, GA; Yang, TJ1
Castel, S; Dawson, R; Dooley, KE; Ignatius, EH; Joubert, A; Kellermann, T; Malo, A; Norman, J; Wiesner, L1
Nambiar, S; Schumann, K; Walinsky, S1
Begum, A; Fatima, N; Heba, SF; Parveen, U; Rafi, R; Sultana, S1
Biswas, S; Deb, U1
Pregnolato, M; Taccani, M; Terreni, M1
Abdel-Rahman, SM; Mirzayev, F; Stancil, SL1
de Jong, BC; Decroo, T; Gils, T; Lynen, L; Van Deun, A1
Ang, CW; Blaskovich, MAT; Cooper, MA; Popat, A; Qu, Z; Tan, L; West, NP1
Campino, S; Clark, TG; Gomes, P; Gómez-González, PJ; Hibberd, ML; Napier, G; Perdigao, J; Phelan, JE; Portugal, I; Puyen, ZM; Santos-Lazaro, D; Viveiros, M1
He, W; Li, F; Shen, C; Wang, S; Wang, Y; Xia, H; Zhao, B; Zhao, Y; Zheng, H1
Avaliani, Z; Conradie, F; Cook-Scalise, S; Everitt, D; Garfin, AMC; Gomez, GB; Juneja, S; Kiria, N; Lomtadze, N; Malhotra, S; Ndjeka, N; Siapka, M; Spigelman, M; Vassall, A1
Howell, P; Mvuna, N; Olugbosi, M; Upton, C1
Almoslem, M; Drusano, GL; Duncanson, B; Kim, S; Louie, A; Myrick, J; Neely, M; Nole, J; Peloquin, CA; Scanga, CA; Schmidt, S; Yamada, W1
Cook-Scalise, S; Edo, P; Gebhard, A; Juneja, S; Kadyrov, A; Lawanson, A; Malhotra, S; Mambetova, E; Mulder, C; Pambudi, I; Rupert, S; Setiawan, E; Sohn, H; Sugiharto, J; Useni, S; van den Hof, S1
Bax, HI; De Steenwinkel, JEM; Lenaerts, A; Mudde, SE; Upton, AM1
Andres, S; Bateson, A; Borroni, E; Cirillo, DM; Dippenaar, A; Feuerriegel, S; Ghodousi, A; Groenheit, R; Kohl, TA; Köser, CU; Kranzer, K; Machado, D; Maurer, FP; McHugh, TD; Merker, M; Niemann, S; Ortiz Canseco, J; Sirgel, F; Sun, E; Timm, J; Toro, JC; Utpatel, C; Viveiros, M; Warren, RM; Werngren, J; Wijkander, M; Witney, AA1
Shaheer, M; Singh, R; Sobhia, ME1
Hui, AM; Li, K; Liu, Y; Lu, Z; Tan, Y; Wei, G; Yang, B1
Betteridge, M; Boekelheide, K; Everitt, D; Nedelman, J; Olugbosi, M; Smith, E; Spigelman, M; Sun, E1
Alffenaar, J; Burke, A; Denholm, J1
Devaleenal, B; Mandal, S; Mattoo, S; Padmapriyadarsini, C; Parmar, M; Ponnuraja, C; Ramraj, B; Singla, R1
Bagdasaryan, TR; Bateson, A; Borisov, S; Conradie, F; Crook, AM; Egizi, E; Everitt, D; Fabiane, SM; Foraida, S; Holsta, A; Howell, P; Hunt, R; Li, M; McHugh, TD; Mendel, CM; Mikiashvili, L; Ngubane, N; Olugbosi, M; Samoilova, A; Skornykova, S; Spigelman, M; Sun, E; Timm, J; Tudor, E; Tweed, CD; Variava, E; Wills, GH; Yablonskiy, P1
Ashkin, D; Goswami, ND; Haley, CA1
Juturu, RR; Surapuraju, PKR1
Bekele, F; Fekadu, G; Fetensa, G; Tolossa, T; Turi, E1
Groenheit, R; Grönfors Seeth, C; Karlsson Lindsjö, O; Mansjö, M; Werngren, J1
Barnes, G; Dawson, R; Dooley, KE; Dorman, SE; Friedman, A; Gupte, N; Hendricks, B; Ignatius, EH; Narunsky, K; Smit, T; Whitelaw, C1
Bahr, M; Brosnan, MK; Chen, X; Dannals, RF; De Jesus, P; Erice, C; Flavahan, K; Holt, DP; Jain, SK; Kim, J; Lodge, MA; Mota, F; Ordonez, AA; Peloquin, CA; Ruiz-Bedoya, CA; Tucker, EW1
Nahid, P; Velásquez, GE1
Aarnoutse, R; Andres, S; Choong, E; Decosterd, LA; Dreyer, V; John, A; Kalsdorf, B; Koehler, N; König, C; Krieger, D; Kuhns, M; Lange, C; Maurer, FP; Merker, M; Niemann, S; Peloquin, CA; Sanchez Carballo, PM; Schaub, D; Schön, T; Schönfeld, N; Verougstraete, N; Verstraete, AG; Werngren, J; Wicha, SG; Zur Wiesch, PA1
Guo, T; Mehta, K; van der Graaf, PH; van Hasselt, JGC1
Betoudji, F; Converse, PJ; Fotouhi, N; Lee, J; Li, SY; Mdluli, K; Nuermberger, EL; Upton, A1
Abrahams, KA; Bashiri, G; Batt, SM; Besra, GS; Gurcha, SS; Veerapen, N1
Alffenaar, JC; Anthony, RM; Nguyen, QH; Nguyen, TNT; Nguyen, TVA; Vu, DH1
Abdalla, BJ; Abramovitch, RB; Albrecht, VJ; Eke, IE; Haiderer, ER; Murdoch, HM; Williams, JT1
Ahrenstorf, G; Friesen, I; Joean, O; Kuhns, M; Picksak, G; Ringshausen, FC; Trauth, J; Welte, T1

Reviews

22 review(s) available for azomycin and pa 824

ArticleYear
[Anti-tuberculosis drugs].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 2

    Topics: 4-Quinolones; Anti-Infective Agents; Antitubercular Agents; Chlorpromazine; Drug Delivery Systems; Drug Design; Drug Resistance, Multiple, Bacterial; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Rifamycins

2003
Advances in the treatment of tuberculosis.
    Clinical pharmacology and therapeutics, 2007, Volume: 82, Issue:5

    Topics: Adamantane; AIDS-Related Opportunistic Infections; Animals; Anti-Bacterial Agents; Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Drugs, Investigational; Ethylenediamines; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; Isoniazid; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Rifampin; Treatment Refusal; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary

2007
PA-824.
    Tuberculosis (Edinburgh, Scotland), 2008, Volume: 88, Issue:2

    Topics: Animals; Antitubercular Agents; Humans; Nitroimidazoles; Treatment Outcome; Tuberculosis

2008
New anti-tuberculosis drugs with novel mechanisms of action.
    Current medicinal chemistry, 2008, Volume: 15, Issue:19

    Topics: Adamantane; Animals; Antitubercular Agents; Diarylquinolines; Drug Design; Drug Resistance, Multiple, Bacterial; Ethylenediamines; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Quinolines; Structure-Activity Relationship; Tuberculosis, Pulmonary

2008
The nitroimidazooxazines (PA-824 and analogs): structure-activity relationship and mechanistic studies.
    Future medicinal chemistry, 2010, Volume: 2, Issue:8

    Topics: Animals; Antitubercular Agents; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Structure-Activity Relationship; Tuberculosis

2010
PA-824 , moxifloxacin and pyrazinamide combination therapy for tuberculosis.
    Expert opinion on investigational drugs, 2013, Volume: 22, Issue:7

    Topics: Animals; Antitubercular Agents; Aza Compounds; Clinical Trials as Topic; Drug Combinations; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Molecular Structure; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Quinolines; Tuberculosis, Pulmonary

2013
Tuberculosis: clinical trials and new drug regimens.
    Current opinion in pulmonary medicine, 2014, Volume: 20, Issue:3

    Topics: Acetamides; Adamantane; Antitubercular Agents; Clinical Trials as Topic; Diarylquinolines; Drug Administration Schedule; Drug Design; Ethylenediamines; Female; Fluoroquinolones; Humans; Levofloxacin; Linezolid; Male; Moxifloxacin; Nitroimidazoles; Oxazoles; Oxazolidinones; Spiro Compounds; Thiazines; Tuberculosis; Tuberculosis, Multidrug-Resistant

2014
Managing multidrug-resistant tuberculosis in children: review of recent developments.
    Current opinion in infectious diseases, 2014, Volume: 27, Issue:3

    Topics: Antitubercular Agents; Child; Child, Preschool; Directly Observed Therapy; Drug Administration Schedule; Ethionamide; Fluoroquinolones; Humans; Infant; Moxifloxacin; Nitroimidazoles; Practice Guidelines as Topic; Prevalence; Pyrazinamide; Risk Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant

2014
Novel drugs against tuberculosis: a clinician's perspective.
    The European respiratory journal, 2015, Volume: 45, Issue:4

    Topics: Adamantane; Antitubercular Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diarylquinolines; Drug Therapy, Combination; Ethylenediamines; Extensively Drug-Resistant Tuberculosis; Female; Follow-Up Studies; Humans; Male; Nitroimidazoles; Oxazoles; Oxazolidinones; Treatment Outcome; Tuberculosis, Multidrug-Resistant

2015
ADVANCES IN PHARMACOTHERAPY OF TUBERCULOSIS.
    Acta poloniae pharmaceutica, 2017, Volume: 74, Issue:1

    Topics: Antitubercular Agents; Clinical Trials as Topic; Diarylquinolines; Humans; Nitroimidazoles; Oxazolidinones; Tuberculosis, Multidrug-Resistant

2017
New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis.
    Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia, 2018, Volume: 44, Issue:2

    Topics: Antitubercular Agents; Clinical Trials as Topic; Diarylquinolines; Drug Repositioning; Extensively Drug-Resistant Tuberculosis; Humans; Nitroimidazoles; Oxazoles

2018
New drugs to treat difficult tuberculous and nontuberculous mycobacterial pulmonary disease.
    Current opinion in pulmonary medicine, 2019, Volume: 25, Issue:3

    Topics: Amikacin; Anti-Bacterial Agents; Clofazimine; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Humans; Linezolid; Liposomes; Lung Diseases; Microbial Sensitivity Tests; Mycobacterium Infections, Nontuberculous; Nitroimidazoles; Oxazoles

2019
The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis.
    The Lancet. Respiratory medicine, 2019, Volume: 7, Issue:9

    Topics: Antitubercular Agents; Diarylquinolines; Drug Therapy, Combination; Humans; Linezolid; Nitroimidazoles; Oxazoles; Periodicals as Topic; Pulmonary Medicine; Societies, Medical; Tuberculosis; Tuberculosis, Multidrug-Resistant

2019
Pretomanid: First Approval.
    Drugs, 2019, Volume: 79, Issue:16

    Topics: Anti-Bacterial Agents; Antifungal Agents; Drug Approval; Humans; Nitroimidazoles; Tuberculosis; United States

2019
Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid.
    The Journal of antimicrobial chemotherapy, 2020, 08-01, Volume: 75, Issue:8

    Topics: Antitubercular Agents; Clofazimine; Diarylquinolines; Humans; Linezolid; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pharmaceutical Preparations; Tuberculosis, Multidrug-Resistant

2020
Pretomanid: A novel therapeutic paradigm for treatment of drug resistant tuberculosis.
    The Indian journal of tuberculosis, 2021, Volume: 68, Issue:1

    Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; Nitroimidazoles; Tuberculosis, Multidrug-Resistant

2021
Pretomanid: The latest USFDA-approved anti-tuberculosis drug.
    The Indian journal of tuberculosis, 2021, Volume: 68, Issue:2

    Topics: Antitubercular Agents; Drug Approval; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Humans; Nitroimidazoles; United States; United States Food and Drug Administration

2021
New Antibiotics for Multidrug-Resistant Bacterial Strains: Latest Research Developments and Future Perspectives.
    Molecules (Basel, Switzerland), 2021, May-02, Volume: 26, Issue:9

    Topics: Animals; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Boronic Acids; Cefiderocol; Cephalosporins; Chemistry, Pharmaceutical; Clostridioides difficile; Clostridium Infections; Drug Design; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gonorrhea; Humans; Meropenem; Neisseria gonorrhoeae; Nitroimidazoles; Sisomicin; Tetracyclines

2021
Profiling Pretomanid as a Therapeutic Option for TB Infection: Evidence to Date.
    Drug design, development and therapy, 2021, Volume: 15

    Topics: Animals; Antitubercular Agents; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Humans; Nitroimidazoles; Tuberculosis, Multidrug-Resistant

2021
Pretomanid for tuberculosis: a systematic review.
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2022, Volume: 28, Issue:1

    Topics: Antitubercular Agents; Humans; Linezolid; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Randomized Controlled Trials as Topic; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant

2022
Pretomanid development and its clinical roles in treating tuberculosis.
    Journal of global antimicrobial resistance, 2022, Volume: 31

    Topics: Antitubercular Agents; Humans; Nitroimidazoles; Tuberculosis; Tuberculosis, Multidrug-Resistant

2022
Pretomanid resistance: An update on emergence, mechanisms and relevance for clinical practice.
    International journal of antimicrobial agents, 2023, Volume: 62, Issue:4

    Topics: Animals; Antitubercular Agents; Mycobacterium tuberculosis; Nitroimidazoles; Tuberculosis; Tuberculosis, Multidrug-Resistant

2023

Trials

19 trial(s) available for azomycin and pa 824

ArticleYear
Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:9

    Topics: Adult; Antitubercular Agents; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Nitroimidazoles; Young Adult

2009
Assessment of the effects of the nitroimidazo-oxazine PA-824 on renal function in healthy subjects.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:9

    Topics: Adult; Antitubercular Agents; Blood Urea Nitrogen; Creatinine; Female; Glomerular Filtration Rate; Humans; Kidney; Kidney Function Tests; Male; Middle Aged; Nitroimidazoles; Renal Plasma Flow, Effective; Young Adult

2009
Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:8

    Topics: Adult; Antitubercular Agents; Colony Count, Microbial; Culture Media; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Mycobacterium tuberculosis; Nitroimidazoles; Sputum; Treatment Outcome; Tuberculosis, Pulmonary; Young Adult

2010
Phase II dose-ranging trial of the early bactericidal activity of PA-824.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:6

    Topics: Adolescent; Adult; Antitubercular Agents; Drug Administration Schedule; Ethambutol; Female; Humans; Isoniazid; Male; Middle Aged; Nitroimidazoles; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary; Young Adult

2012
14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial.
    Lancet (London, England), 2012, Sep-15, Volume: 380, Issue:9846

    Topics: Adult; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Diarylquinolines; Double-Blind Method; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Male; Microbial Viability; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Prospective Studies; Pyrazinamide; Quinolines; Sputum; Tuberculosis, Pulmonary; Young Adult

2012
Evaluation of pharmacokinetic interaction between PA-824 and midazolam in healthy adult subjects.
    Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:8

    Topics: Adolescent; Adult; Area Under Curve; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Midazolam; Middle Aged; Nitroimidazoles; Time Factors; Young Adult

2013
Effect of a high-calorie, high-fat meal on the bioavailability and pharmacokinetics of PA-824 in healthy adult subjects.
    Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:11

    Topics: Administration, Oral; Adult; Antitubercular Agents; Area Under Curve; Biological Availability; Cross-Over Studies; Dietary Fats; Drug Administration Schedule; Fasting; Female; Food-Drug Interactions; Healthy Volunteers; Humans; Male; Middle Aged; Nitroimidazoles

2013
Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:9

    Topics: Adult; Alkynes; Antitubercular Agents; Antiviral Agents; Benzoxazines; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; Humans; Lopinavir; Male; Middle Aged; Nitroimidazoles; Pharmacogenetics; Rifampin; Ritonavir; Young Adult

2014
Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline.
    American journal of respiratory and critical care medicine, 2015, Apr-15, Volume: 191, Issue:8

    Topics: Adult; Antitubercular Agents; Clofazimine; Diarylquinolines; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Nitroimidazoles; Pyrazinamide; Treatment Outcome; Tuberculosis; Tuberculosis, Multidrug-Resistant

2015
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pul
    Lancet (London, England), 2015, May-02, Volume: 385, Issue:9979

    Topics: Adolescent; Adult; Antitubercular Agents; Colony Count, Microbial; Drug Therapy, Combination; Ethambutol; Female; Fluoroquinolones; Humans; Isoniazid; Male; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Rifampin; South Africa; Sputum; Tanzania; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult

2015
Long-Term Effects on QT Prolongation of Pretomanid Alone and in Combinations in Patients with Tuberculosis.
    Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:10

    Topics: Antitubercular Agents; Computer Simulation; Diarylquinolines; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Heart Rate; Humans; Linezolid; Long QT Syndrome; Models, Statistical; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Tuberculosis, Multidrug-Resistant

2019
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial.
    The Lancet. Respiratory medicine, 2019, Volume: 7, Issue:12

    Topics: Antitubercular Agents; Diarylquinolines; Drug Administration Schedule; Drug Therapy, Combination; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Rifampin; South Africa; Sputum; Tanzania; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Uganda

2019
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis.
    The New England journal of medicine, 2020, 03-05, Volume: 382, Issue:10

    Topics: Administration, Oral; Adolescent; Adult; Antitubercular Agents; Bacterial Load; Diarylquinolines; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Female; Humans; Intention to Treat Analysis; Linezolid; Male; Middle Aged; Mycobacterium tuberculosis; Nitroimidazoles; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult

2020
Phase 1 Study of the Effects of the Tuberculosis Treatment Pretomanid, Alone and in Combination With Moxifloxacin, on the QTc Interval in Healthy Volunteers.
    Clinical pharmacology in drug development, 2021, Volume: 10, Issue:6

    Topics: Adolescent; Adult; Antitubercular Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Electrocardiography; Female; Humans; Long QT Syndrome; Male; Middle Aged; Moxifloxacin; Nitroimidazoles; Young Adult

2021
Pretomanid dose selection for pulmonary tuberculosis: An application of multi-objective optimization to dosage regimen design.
    CPT: pharmacometrics & systems pharmacology, 2021, Volume: 10, Issue:3

    Topics: Adult; Antitubercular Agents; Colony-Forming Units Assay; Computer Simulation; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Nitroimidazoles; Safety; Sputum; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary

2021
Safety and pharmacokinetic profile of pretomanid in healthy Chinese adults: Results of a phase I single dose escalation study.
    Pulmonary pharmacology & therapeutics, 2022, Volume: 73-74

    Topics: Adult; Area Under Curve; Asian People; China; Dose-Response Relationship, Drug; Double-Blind Method; Female; Healthy Volunteers; Humans; Hyperbilirubinemia; Male; Nitroimidazoles; Young Adult

2022
Randomised trial to evaluate the effectiveness and safety of varying doses of linezolid with bedaquiline and pretomanid in adults with pre-extensively drug-resistant or treatment intolerant/non-responsive multidrug-resistant pulmonary tuberculosis: study
    BMJ open, 2022, 08-29, Volume: 12, Issue:8

    Topics: Adult; Antitubercular Agents; Diarylquinolines; Humans; Linezolid; Nitroimidazoles; Randomized Controlled Trials as Topic; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary

2022
Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis.
    The New England journal of medicine, 2022, 09-01, Volume: 387, Issue:9

    Topics: Aminoglycosides; Antitubercular Agents; Diarylquinolines; Fluoroquinolones; Humans; Linezolid; Nitroimidazoles; Rifampin; Risk Assessment; Treatment Outcome; Tuberculosis; Tuberculosis, Multidrug-Resistant

2022
Assessing Pretomanid for Tuberculosis (APT), a Randomized Phase 2 Trial of Pretomanid-Containing Regimens for Drug-Sensitive Tuberculosis: 12-Week Results.
    American journal of respiratory and critical care medicine, 2023, 04-01, Volume: 207, Issue:7

    Topics: Animals; Antitubercular Agents; Drug Therapy, Combination; Isoniazid; Mice; Nitroimidazoles; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary

2023

Other Studies

137 other study(ies) available for azomycin and pa 824

ArticleYear
A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.
    Nature, 2000, Jun-22, Volume: 405, Issue:6789

    Topics: Animals; Antitubercular Agents; Bacterial Proteins; Drug Resistance, Microbial; Drug Resistance, Multiple; Guinea Pigs; Lipids; Metronidazole; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Structure-Activity Relationship; Tuberculosis

2000
Use of transposon Tn5367 mutagenesis and a nitroimidazopyran-based selection system to demonstrate a requirement for fbiA and fbiB in coenzyme F(420) biosynthesis by Mycobacterium bovis BCG.
    Journal of bacteriology, 2001, Volume: 183, Issue:24

    Topics: Antitubercular Agents; Bacterial Proteins; Coenzymes; DNA Transposable Elements; Drug Resistance, Bacterial; Enzymes; Genes, Bacterial; Genetic Complementation Test; Multigene Family; Mutagenesis, Insertional; Mycobacterium bovis; Nitroimidazoles; Operon; Riboflavin; Sequence Analysis, DNA; Transcription, Genetic

2001
Demonstration that fbiC is required by Mycobacterium bovis BCG for coenzyme F(420) and FO biosynthesis.
    Journal of bacteriology, 2002, Volume: 184, Issue:9

    Topics: Cloning, Molecular; DNA Transposable Elements; Escherichia coli; Genes, Bacterial; Genetic Complementation Test; Histidine; Molecular Sequence Data; Multigene Family; Mutagenesis, Insertional; Mycobacterium bovis; Nitroimidazoles; Riboflavin

2002
Tuberculosis: new drug class investigated through public-private partnership.
    AIDS treatment news, 2000, Jul-07, Issue:346

    Topics: Antitubercular Agents; Cooperative Behavior; Humans; Nitroimidazoles; Private Sector; Public Sector; Tuberculosis

2000
Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis.
    Antimicrobial agents and chemotherapy, 2005, Volume: 49, Issue:6

    Topics: Animals; Antitubercular Agents; Colony Count, Microbial; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Resistance, Bacterial; Female; Humans; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Random Allocation; Tuberculosis, Pulmonary

2005
Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models.
    Antimicrobial agents and chemotherapy, 2005, Volume: 49, Issue:6

    Topics: Animals; Antitubercular Agents; Colony Count, Microbial; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Humans; Lung; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Specific Pathogen-Free Organisms; Spleen; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary

2005
New tuberculosis drug enters human trials.
    The Lancet. Infectious diseases, 2005, Volume: 5, Issue:8

    Topics: Antitubercular Agents; Clinical Trials as Topic; Humans; Nitroimidazoles; Tuberculosis

2005
Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis.
    Proceedings of the National Academy of Sciences of the United States of America, 2006, Jan-10, Volume: 103, Issue:2

    Topics: Bacterial Proteins; DNA Transposable Elements; Drug Resistance, Bacterial; Genome, Bacterial; Glucosephosphate Dehydrogenase; Molecular Sequence Data; Molecular Structure; Mutation; Mycobacterium tuberculosis; Nitroimidazoles; Oxazines; Phenotype

2006
NIAID researchers make key discovery in development of TB drug candidate.
    Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2006, Volume: 54, Issue:2

    Topics: Antitubercular Agents; Drug Design; Drug Resistance, Bacterial; Mycobacterium tuberculosis; National Institutes of Health (U.S.); Nitroimidazoles; United States

2006
Bactericidal activities of R207910 and other newer antimicrobial agents against Mycobacterium leprae in mice.
    Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:4

    Topics: Acetamides; Animals; Anti-Infective Agents; Aza Compounds; Diarylquinolines; Female; Fluoroquinolones; Leprosy; Linezolid; Mice; Moxifloxacin; Mycobacterium leprae; Nitroimidazoles; Oxazolidinones; Quinolines

2006
In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans.
    Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:6

    Topics: Acetamides; Amikacin; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Colony Count, Microbial; Diarylquinolines; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Foot; In Vitro Techniques; Linezolid; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Mycobacterium ulcerans; Nitroimidazoles; Oxazolidinones; Quinolines; Rifampin; Streptomycin; Survival Analysis; Time Factors

2006
Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis.
    Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:8

    Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Disease Models, Animal; Drug Therapy, Combination; Ethambutol; Female; Isoniazid; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Rifampin; Secondary Prevention; Time Factors; Tuberculosis, Pulmonary

2006
Mycobacterium leprae is naturally resistant to PA-824.
    Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:10

    Topics: Animals; Culture Media; Disease Models, Animal; Drug Resistance, Bacterial; Leprosy; Macrophages, Peritoneal; Mice; Mice, Inbred BALB C; Mice, Nude; Microbial Sensitivity Tests; Mycobacterium leprae; Nitroimidazoles

2006
NLCQ-1 and NLCQ-2, two new agents with activity against dormant Mycobacterium tuberculosis.
    International journal of antimicrobial agents, 2007, Volume: 29, Issue:6

    Topics: Animals; Antitubercular Agents; Chlorocebus aethiops; Imidazoles; Inhibitory Concentration 50; Mycobacterium tuberculosis; Nitroimidazoles; Prodrugs; Quinolines; Time Factors; Vero Cells

2007
Comparison of the sterilising activities of the nitroimidazopyran PA-824 and moxifloxacin against persisting Mycobacterium tuberculosis.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2008, Volume: 12, Issue:1

    Topics: Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Dose-Response Relationship, Drug; Fluoroquinolones; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Quinolines; Time Factors

2008
Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis.
    Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:4

    Topics: Animals; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Disease Models, Animal; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Lung; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Quinolines; Treatment Outcome; Tuberculosis, Pulmonary

2008
Synthesis and antitubercular activity of 7-(R)- and 7-(S)-methyl-2-nitro-6-(S)-(4-(trifluoromethoxy)benzyloxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazines, analogues of PA-824.
    Bioorganic & medicinal chemistry letters, 2008, Apr-01, Volume: 18, Issue:7

    Topics: Antitubercular Agents; Crystallography, X-Ray; Drug Resistance, Bacterial; Mycobacterium tuberculosis; Nitroimidazoles; Oxazines; Oxazoles; Stereoisomerism; Structure-Activity Relationship

2008
Crystal structures of F420-dependent glucose-6-phosphate dehydrogenase FGD1 involved in the activation of the anti-tuberculosis drug candidate PA-824 reveal the basis of coenzyme and substrate binding.
    The Journal of biological chemistry, 2008, Jun-20, Volume: 283, Issue:25

    Topics: Amino Acid Sequence; Antitubercular Agents; Crystallography, X-Ray; Glucosephosphate Dehydrogenase; Kinetics; Models, Chemical; Molecular Conformation; Molecular Sequence Data; Mycobacterium smegmatis; Mycobacterium tuberculosis; Nitroimidazoles; Protein Binding; Protein Conformation; Sequence Homology, Amino Acid; Substrate Specificity

2008
[Some new antitubercular agents].
    Revue medicale suisse, 2008, Mar-19, Volume: 4, Issue:149

    Topics: Acetamides; Antitubercular Agents; Diarylquinolines; Humans; Linezolid; Nitroimidazoles; Oxazoles; Oxazolidinones; Quinolines

2008
Intermediates in the reduction of the antituberculosis drug PA-824, (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine, in aqueous solution.
    Organic & biomolecular chemistry, 2008, Jun-07, Volume: 6, Issue:11

    Topics: Antitubercular Agents; Chromatography, High Pressure Liquid; Magnetic Resonance Spectroscopy; Models, Molecular; Nitroimidazoles; Oxidation-Reduction; Solutions; Spectrometry, Mass, Electrospray Ionization; Spectrophotometry, Ultraviolet; Water

2008
Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis.
    Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:10

    Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Isoniazid; Lung; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Nitroimidazoles; Pyrazinamide; Recurrence; Rifampin; Tuberculosis, Pulmonary

2008
Microbiology. An antibiotic mimics immunity.
    Science (New York, N.Y.), 2008, Nov-28, Volume: 322, Issue:5906

    Topics: Anaerobiosis; Antitubercular Agents; Glucosephosphate Dehydrogenase; Humans; Mycobacterium tuberculosis; Nitric Oxide; Nitroimidazoles; Nitroreductases; Reactive Nitrogen Species; Riboflavin; Tuberculosis

2008
PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release.
    Science (New York, N.Y.), 2008, Nov-28, Volume: 322, Issue:5906

    Topics: Anaerobiosis; Antitubercular Agents; Glucosephosphate Dehydrogenase; Immunity, Innate; Mycobacterium tuberculosis; Nitric Oxide; Nitric Oxide Donors; Nitroimidazoles; Nitroreductases; Oxidation-Reduction; Prodrugs; Reactive Nitrogen Species; Riboflavin; Stereoisomerism

2008
Synthesis, reduction potentials, and antitubercular activity of ring A/B analogues of the bioreductive drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824).
    Journal of medicinal chemistry, 2009, Feb-12, Volume: 52, Issue:3

    Topics: Animals; Antitubercular Agents; Chlorocebus aethiops; Mycobacterium tuberculosis; Nitroimidazoles; Oxazines; Oxidation-Reduction; Vero Cells

2009
Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:4

    Topics: Administration, Inhalation; Aerosols; Animals; Antitubercular Agents; Guinea Pigs; Male; Nitroimidazoles; Powders

2009
Synthesis and structure-activity studies of biphenyl analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824).
    Journal of medicinal chemistry, 2010, Jan-14, Volume: 53, Issue:1

    Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Evaluation, Preclinical; Mice; Mice, Inbred BALB C; Molecular Structure; Mycobacterium tuberculosis; Nitroimidazoles; Stereoisomerism; Structure-Activity Relationship

2010
Release of nitrite from the antitubercular nitroimidazole drug PA-824 and analogues upon one-electron reduction in protic, non-aqueous solvent.
    Organic & biomolecular chemistry, 2010, Jan-21, Volume: 8, Issue:2

    Topics: Aerobiosis; Antitubercular Agents; Electron Transport; Hypoxia; Mass Spectrometry; Mycobacterium tuberculosis; Nitriles; Nitrites; Nitrobenzenes; Nitroimidazoles; Pulse Radiolysis; Reactive Nitrogen Species; Solvents; Spectrophotometry, Ultraviolet; Water

2010
Dry powder PA-824 aerosols for treatment of tuberculosis in guinea pigs.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:4

    Topics: Administration, Inhalation; Administration, Oral; Aerosols; Animals; Antitubercular Agents; Chemistry, Pharmaceutical; Colony Count, Microbial; Disease Models, Animal; Extensively Drug-Resistant Tuberculosis; Guinea Pigs; Humans; Latent Tuberculosis; Lung; Male; Nitroimidazoles; Particle Size; Powders; Spleen; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary

2010
Simple model for testing drugs against nonreplicating Mycobacterium tuberculosis.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:10

    Topics: Antitubercular Agents; Aza Compounds; Fluoroquinolones; Isoniazid; Meropenem; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Quinolines; Rifampin; Streptomycin; Thienamycins

2010
A concise and convergent synthesis of PA-824.
    The Journal of organic chemistry, 2010, Nov-05, Volume: 75, Issue:21

    Topics: Antitubercular Agents; Drug Resistance, Multiple; Hydrolysis; Kinetics; Nitroimidazoles; Stereoisomerism

2010
PA-824 exhibits time-dependent activity in a murine model of tuberculosis.
    Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:1

    Topics: Animals; Antitubercular Agents; Female; Humans; Mice; Nitroimidazoles; Tuberculosis

2011
Comparative bioactivation of the novel anti-tuberculosis agent PA-824 in Mycobacteria and a subcellular fraction of human liver.
    British journal of pharmacology, 2011, Volume: 162, Issue:1

    Topics: Antitubercular Agents; Base Sequence; Biotransformation; DNA Primers; Humans; Liver; Mass Spectrometry; Mycobacterium smegmatis; Mycobacterium tuberculosis; Nitroimidazoles; Subcellular Fractions

2011
Synthesis and structure-activity relationships of aza- and diazabiphenyl analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824).
    Journal of medicinal chemistry, 2010, Dec-09, Volume: 53, Issue:23

    Topics: Animals; Antitubercular Agents; Disease Models, Animal; Magnetic Resonance Spectroscopy; Male; Mice; Mice, Inbred BALB C; Nitroimidazoles; Oxazines; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Tuberculosis

2010
Half-century-old TB drugs get a facelift in new cocktails.
    Nature medicine, 2010, Volume: 16, Issue:12

    Topics: Antitubercular Agents; Aza Compounds; Clinical Trials as Topic; Drug Discovery; Drug Therapy, Combination; Fluoroquinolones; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Quinolines; Tuberculosis

2010
The effect of 5-substitution on the electrochemical behavior and antitubercular activity of PA-824.
    Bioorganic & medicinal chemistry letters, 2011, Jan-15, Volume: 21, Issue:2

    Topics: Antitubercular Agents; Electrochemistry; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Oxidation-Reduction; Tuberculosis

2011
Pharmacophore modeling and density functional theory analysis for a series of nitroimidazole compounds with antitubercular activity.
    Chemical biology & drug design, 2011, Volume: 78, Issue:3

    Topics: Antitubercular Agents; Drug Design; Humans; Models, Biological; Models, Molecular; Mycobacterium tuberculosis; Nitroimidazoles; Quantitative Structure-Activity Relationship; Quantum Theory; Tuberculosis

2011
Structure-activity relationships of antitubercular nitroimidazoles. 3. Exploration of the linker and lipophilic tail of ((s)-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-yl)-(4-trifluoromethoxybenzyl)amine (6-amino PA-824).
    Journal of medicinal chemistry, 2011, Aug-25, Volume: 54, Issue:16

    Topics: Animals; Antitubercular Agents; Bacterial Proteins; Drug Evaluation, Preclinical; Humans; Kinetics; Metabolic Clearance Rate; Mice; Microbial Sensitivity Tests; Microsomes, Liver; Molecular Structure; Mycobacterium tuberculosis; Nitroimidazoles; Nitroreductases; Prodrugs; Structure-Activity Relationship; Substrate Specificity; Tuberculosis

2011
Synthesis and structure-activity relationships of varied ether linker analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine (PA-824).
    Journal of medicinal chemistry, 2011, Oct-13, Volume: 54, Issue:19

    Topics: Acute Disease; Animals; Antitubercular Agents; Chronic Disease; Ethers; Humans; In Vitro Techniques; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Microsomes, Liver; Mycobacterium tuberculosis; Nitroimidazoles; Stereoisomerism; Structure-Activity Relationship; Tuberculosis, Pulmonary

2011
The TB Alliance: overcoming challenges to chart the future course of TB drug development.
    Future medicinal chemistry, 2011, Volume: 3, Issue:10

    Topics: Antitubercular Agents; Aza Compounds; Clinical Trials as Topic; Diarylquinolines; Drug Evaluation, Preclinical; Fluoroquinolones; Humans; Models, Organizational; Moxifloxacin; Nitroimidazoles; Quinolines; Tuberculosis

2011
Integrative analysis of transcriptome and genome indicates two potential genomic islands are associated with pathogenesis of Mycobacterium tuberculosis.
    Gene, 2011, Dec-01, Volume: 489, Issue:1

    Topics: Base Sequence; Down-Regulation; Gene Expression Profiling; Genomic Islands; Lipids; Molecular Sequence Data; Mycobacterium tuberculosis; Nitroimidazoles

2011
Impact of Fgd1 and ddn diversity in Mycobacterium tuberculosis complex on in vitro susceptibility to PA-824.
    Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:12

    Topics: Antitubercular Agents; Bacterial Proteins; Drug Resistance, Bacterial; Genetic Variation; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Polymorphism, Single Nucleotide; Sequence Analysis, DNA

2011
Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis.
    Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:12

    Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Diarylquinolines; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combination; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Nitroimidazoles; Quinolines; Secondary Prevention; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary

2011
Substrate specificity of the deazaflavin-dependent nitroreductase from Mycobacterium tuberculosis responsible for the bioreductive activation of bicyclic nitroimidazoles.
    The FEBS journal, 2012, Volume: 279, Issue:1

    Topics: Antitubercular Agents; Cloning, Molecular; Flavins; Kinetics; Mycobacterium tuberculosis; Nitric Oxide; Nitroimidazoles; Nitroreductases; Oxazoles; Protein Conformation; Stereoisomerism; Structure-Activity Relationship; Substrate Specificity

2012
Structure-activity relationships for amide-, carbamate-, and urea-linked analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824).
    Journal of medicinal chemistry, 2012, Jan-12, Volume: 55, Issue:1

    Topics: Acute Disease; Amides; Animals; Antitubercular Agents; Biological Availability; Biphenyl Compounds; Bridged Bicyclo Compounds, Heterocyclic; Carbamates; Chronic Disease; Dogs; Humans; Mice; Microbial Sensitivity Tests; Microsomes, Liver; Models, Molecular; Mycobacterium tuberculosis; Nitroimidazoles; Piperazines; Rats; Solubility; Stereoisomerism; Structure-Activity Relationship; Tuberculosis, Pulmonary; Urea

2012
Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions.
    The Journal of infectious diseases, 2012, Feb-15, Volume: 205, Issue:4

    Topics: Animals; Antitubercular Agents; Aza Compounds; Disease Models, Animal; Fluoroquinolones; Gene Expression Profiling; Genes, Bacterial; Granuloma; Hypoxia; Immunohistochemistry; Male; Mice; Mice, Inbred C3H; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Positron-Emission Tomography; Pyrazinamide; Quinolines; Treatment Outcome; Tuberculosis

2012
Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide.
    PloS one, 2012, Volume: 7, Issue:1

    Topics: Adamantane; Antitubercular Agents; Diarylquinolines; Drug Monitoring; Drug Therapy, Combination; Ethylenediamines; Extensively Drug-Resistant Tuberculosis; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazolidinones; Pyrazinamide; Quinolines; Reproducibility of Results; Time Factors

2012
Trial tests new combination of drugs to treat tuberculosis.
    BMJ (Clinical research ed.), 2012, Mar-20, Volume: 344

    Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Aza Compounds; Clinical Trials as Topic; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Humans; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Quinolines; Research Support as Topic; Tuberculosis; United States

2012
Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:6

    Topics: Animals; Antitubercular Agents; Drug Therapy, Combination; Female; Isoniazid; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Nitroimidazoles; Oxazolidinones; Pyrazinamide; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant

2012
In vitro activities of the new antitubercular agents PA-824 and BTZ043 against Nocardia brasiliensis.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:7

    Topics: Antitubercular Agents; Microbial Sensitivity Tests; Nitroimidazoles; Nocardia

2012
New drug combination for TB is tested in unique trial.
    BMJ (Clinical research ed.), 2012, Jul-25, Volume: 345

    Topics: Antitubercular Agents; Aza Compounds; Clinical Trials as Topic; Drug Combinations; Fluoroquinolones; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Quinolines; Tuberculosis

2012
In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:11

    Topics: Adamantane; Antitubercular Agents; Aza Compounds; Diarylquinolines; Drug Combinations; Drug Synergism; Ethambutol; Ethylenediamines; Fluoroquinolones; Isoniazid; Meropenem; Microbial Sensitivity Tests; Microbial Viability; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Quinolines; Rifampin; Spiro Compounds; Thiazines; Thienamycins

2012
Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen.
    Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:8

    Topics: Animals; Antitubercular Agents; Area Under Curve; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Guinea Pigs; Lung; Mycobacterium tuberculosis; Nitroimidazoles; Organ Size; Pyrazinamide; Recurrence; Rifamycins; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary

2013
Bactericidal activity of PA-824 against Mycobacterium tuberculosis under anaerobic conditions and computational analysis of its novel analogues against mutant Ddn receptor.
    BMC microbiology, 2013, Oct-01, Volume: 13

    Topics: Anaerobiosis; Antitubercular Agents; Colony Count, Microbial; Drug Resistance, Bacterial; Humans; Microbial Viability; Molecular Docking Simulation; Mutant Proteins; Mycobacterium tuberculosis; Nitroimidazoles; Nitroreductases

2013
Rv0132c of Mycobacterium tuberculosis encodes a coenzyme F420-dependent hydroxymycolic acid dehydrogenase.
    PloS one, 2013, Volume: 8, Issue:12

    Topics: Amino Acid Sequence; Antitubercular Agents; Bacterial Proteins; Cell Wall; Gene Expression; Humans; Kinetics; Molecular Sequence Data; Mycobacterium tuberculosis; Mycolic Acids; Nitroimidazoles; Oxidoreductases; Riboflavin; Sequence Alignment; Sequence Homology, Amino Acid; Substrate Specificity

2013
LC-MS/MS method for the simultaneous determination of PA-824, moxifloxacin and pyrazinamide in rat plasma and its application to pharmacokinetic study.
    Journal of pharmaceutical and biomedical analysis, 2014, Volume: 97

    Topics: Animals; Chromatography, Liquid; Drug Interactions; Fluoroquinolones; Limit of Detection; Metronidazole; Moxifloxacin; Nitroimidazoles; Plasma; Pyrazinamide; Rats; Tandem Mass Spectrometry

2014
Pharmacokinetics-pharmacodynamics analysis of bicyclic 4-nitroimidazole analogs in a murine model of tuberculosis.
    PloS one, 2014, Volume: 9, Issue:8

    Topics: Animals; Caco-2 Cells; Cell Line, Tumor; Disease Models, Animal; Female; Humans; Mice; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Retrospective Studies; Tuberculosis

2014
PA-824 is as effective as isoniazid against latent tuberculosis infection in C3HeB/FeJ mice.
    International journal of antimicrobial agents, 2014, Volume: 44, Issue:6

    Topics: Animals; Antitubercular Agents; Disease Models, Animal; Female; Isoniazid; Latent Tuberculosis; Lung; Mice; Mice, Inbred C3H; Mycobacterium tuberculosis; Nitroimidazoles; Rifampin

2014
In vitro and in vivo activities of the nitroimidazole TBA-354 against Mycobacterium tuberculosis.
    Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:1

    Topics: Animals; Antitubercular Agents; Caco-2 Cells; Cell Line, Tumor; Disease Models, Animal; Drug Interactions; Drug Resistance, Bacterial; Female; Humans; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazines; Oxazoles; Tuberculosis

2015
Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis.
    Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:1

    Topics: Animals; Antitubercular Agents; Clofazimine; Diarylquinolines; Disease Models, Animal; Drug Therapy, Combination; Female; Fluoroquinolones; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Oxazines; Oxazoles; Pyrazinamide; Random Allocation; Tuberculosis

2015
A novel molecule with notable activity against multi-drug resistant tuberculosis.
    Bioorganic & medicinal chemistry letters, 2015, Mar-15, Volume: 25, Issue:6

    Topics: Antitubercular Agents; Cytochrome P-450 Enzyme System; Drug Design; Drug Synergism; Glucuronosyltransferase; Half-Life; Humans; Microbial Sensitivity Tests; Microsomes, Liver; Mycobacterium tuberculosis; Nitroimidazoles; Piperazines; Pyridones; Tuberculosis, Multidrug-Resistant

2015
Synthesis and structure-activity relationships for extended side chain analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824).
    Journal of medicinal chemistry, 2015, Apr-09, Volume: 58, Issue:7

    Topics: Administration, Oral; Animals; Antitubercular Agents; Biological Availability; Chemistry Techniques, Synthetic; Chronic Disease; Disease Models, Animal; Humans; Male; Mice, Inbred BALB C; Mice, Inbred Strains; Microbial Sensitivity Tests; Microsomes, Liver; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Rats, Sprague-Dawley; Structure-Activity Relationship; Tuberculosis

2015
New effective antituberculosis regimens.
    Lancet (London, England), 2015, May-02, Volume: 385, Issue:9979

    Topics: Antitubercular Agents; Female; Fluoroquinolones; Humans; Male; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary

2015
Determination of the antitubercular drug PA-824 in rat plasma, lung and brain tissues by liquid chromatography tandem mass spectrometry: application to a pharmacokinetic study.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2015, Apr-15, Volume: 988

    Topics: Animals; Antitubercular Agents; Brain Chemistry; Chromatography, Liquid; Drug Stability; Female; Linear Models; Lung; Nitroimidazoles; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry

2015
Structural insights of PA-824 derivatives: ligand-based 3D-QSAR study and design of novel PA824 derivatives as anti-tubercular agents.
    Journal of receptor and signal transduction research, 2015, Volume: 35, Issue:5

    Topics: Antitubercular Agents; Binding Sites; Drug Design; Models, Chemical; Molecular Conformation; Molecular Docking Simulation; Nitroimidazoles; Quantitative Structure-Activity Relationship

2015
Mutations in genes for the F420 biosynthetic pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous in vitro-selected PA-824-resistant mutants of Mycobacterium tuberculosis.
    Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:9

    Topics: Antitubercular Agents; Bacterial Proteins; Drug Resistance, Bacterial; Mutation; Mycobacterium tuberculosis; Nitroimidazoles; Nitroreductases; Polymorphism, Genetic; Protein Structure, Secondary

2015
Synthesis and anti-tubercular activity of 2-nitroimidazooxazines with modification at the C-7 position as PA-824 analogs.
    Bioorganic & medicinal chemistry letters, 2015, Sep-01, Volume: 25, Issue:17

    Topics: Antitubercular Agents; Chemistry Techniques, Synthetic; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Structure-Activity Relationship

2015
Tissue distribution of pretomanid in rat brain via mass spectrometry imaging.
    Xenobiotica; the fate of foreign compounds in biological systems, 2016, Volume: 46, Issue:3

    Topics: Animals; Antitubercular Agents; Blood-Brain Barrier; Brain; Female; Nitroimidazoles; Prodrugs; Rats; Rats, Sprague-Dawley; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tissue Distribution

2016
Rapid, Semiquantitative Assay To Discriminate among Compounds with Activity against Replicating or Nonreplicating Mycobacterium tuberculosis.
    Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:10

    Topics: Agar; Antitubercular Agents; Biological Assay; Charcoal; Colony Count, Microbial; Coloring Agents; Diarylquinolines; Fluorometry; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazines; Xanthenes

2015
glpx Gene in Mycobacterium tuberculosis Is Required for In Vitro Gluconeogenic Growth and In Vivo Survival.
    PloS one, 2015, Volume: 10, Issue:9

    Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; Carbon; Fatty Acids; Fructose-Bisphosphatase; Gene Deletion; Genes, Bacterial; Gluconeogenesis; Mice, Inbred BALB C; Microbial Sensitivity Tests; Microbial Viability; Mycobacterium tuberculosis; Nitroimidazoles; Stress, Physiological; Tuberculosis

2015
Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis.
    Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:1

    Topics: Animals; Antitubercular Agents; Bacterial Load; Diarylquinolines; Disease Models, Animal; Drug Administration Schedule; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Synergism; Female; Linezolid; Lung; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Nitroimidazoles; Organophosphates; Oxazoles; Oxazolidinones; Pyrazinamide; Time Factors; Treatment Outcome; Tuberculosis, Pulmonary

2016
Pharmacokinetics and tissue distribution study of PA-824 in rats by LC-MS/MS.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2015, Dec-01, Volume: 1006

    Topics: Administration, Oral; Animals; Chromatography, Liquid; Linear Models; Nitroimidazoles; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Tissue Distribution

2015
Synthesis and evaluation of pretomanid (PA-824) oxazolidinone hybrids.
    Bioorganic & medicinal chemistry letters, 2016, Jan-15, Volume: 26, Issue:2

    Topics: Animals; Antitubercular Agents; Chronic Disease; Disease Models, Animal; Mice; Mice, Inbred C57BL; Mycobacterium tuberculosis; Nitroimidazoles; Oxazolidinones; Tuberculosis

2016
Simultaneous HPLC assay for pretomanid (PA-824), moxifloxacin and pyrazinamide in an inhaler formulation for drug-resistant tuberculosis.
    Journal of pharmaceutical and biomedical analysis, 2017, Feb-20, Volume: 135

    Topics: Administration, Inhalation; Antitubercular Agents; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Drug Compounding; Fluoroquinolones; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Tuberculosis, Multidrug-Resistant

2017
Snapshot Profiling of the Antileishmanial Potency of Lead Compounds and Drug Candidates against Intracellular Leishmania donovani Amastigotes, with a Focus on Human-Derived Host Cells.
    Antimicrobial agents and chemotherapy, 2017, Volume: 61, Issue:3

    Topics: Animals; Antimony; Antiprotozoal Agents; Cell Differentiation; Cell Line; Host-Pathogen Interactions; Humans; Inhibitory Concentration 50; Leishmania donovani; Macrophages; Mice; Mice, Knockout; Monocytes; Nitroimidazoles; Primary Cell Culture; Stereoisomerism; Tetradecanoylphorbol Acetate

2017
Easier cure for resistant TB.
    Science (New York, N.Y.), 2017, Feb-17, Volume: 355, Issue:6326

    Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Baltimore; Clinical Trials as Topic; Diarylquinolines; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Humans; Linezolid; Mycobacterium tuberculosis; Nitroimidazoles; South Africa; Sputum; Treatment Outcome

2017
TB Alliance regimen development for multidrug-resistant tuberculosis.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2016, 12-01, Volume: 20, Issue:12

    Topics: Antitubercular Agents; Clinical Protocols; Diarylquinolines; Dose-Response Relationship, Drug; Ethambutol; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; Isoniazid; Linezolid; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Randomized Controlled Trials as Topic; Research Design; Rifampin; Tuberculosis, Multidrug-Resistant

2016
6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]thiazoles: Facile synthesis and comparative appraisal against tuberculosis and neglected tropical diseases.
    Bioorganic & medicinal chemistry letters, 2017, 06-01, Volume: 27, Issue:11

    Topics: Animals; Antitubercular Agents; Chagas Disease; Disease Models, Animal; Mice; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Structure-Activity Relationship; Thiazoles; Tuberculosis

2017
Biopharmaceutic parameters, pharmacokinetics, transport and CYP-mediated drug interactions of IIIM-017: A novel nitroimidazooxazole analogue with anti-tuberculosis activity.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2017, Aug-30, Volume: 106

    Topics: Animals; Antitubercular Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Caco-2 Cells; Computer Simulation; Drug Interactions; Humans; Mice, Inbred BALB C; Microsomes, Liver; Nitroimidazoles; Oxazoles

2017
Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis.
    Antimicrobial agents and chemotherapy, 2017, Volume: 61, Issue:9

    Topics: Animals; Antitubercular Agents; Diarylquinolines; Disease Models, Animal; Female; Fluoroquinolones; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Tuberculosis, Pulmonary

2017
Cordyceps sinensis promotes immune regulation and enhances bacteriostatic activity of PA-824 via IL-10 in Mycobacterium tuberculosis disease.
    Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2017, Aug-07, Volume: 50, Issue:9

    Topics: Animals; Anti-Bacterial Agents; Blotting, Western; Cordyceps; Disease Models, Animal; Flow Cytometry; Immunomodulation; Interleukin-10; Male; Mice; Mice, Inbred CBA; Mycobacterium tuberculosis; Nitroimidazoles; Real-Time Polymerase Chain Reaction; Tuberculosis, Pulmonary

2017
Dual Mechanism of Action of 5-Nitro-1,10-Phenanthroline against Mycobacterium tuberculosis.
    Antimicrobial agents and chemotherapy, 2017, Volume: 61, Issue:11

    Topics: Animals; Antitubercular Agents; Autophagy; Cell Line, Tumor; Disease Models, Animal; Escherichia coli; Female; Humans; Macrophages; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Mycobacterium bovis; Mycobacterium smegmatis; Mycobacterium tuberculosis; Nitroimidazoles; Phenanthrolines; Structure-Activity Relationship; THP-1 Cells; Tuberculosis, Multidrug-Resistant

2017
Assessment of a pretomanid analogue library for African trypanosomiasis: Hit-to-lead studies on 6-substituted 2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]thiazine 8-oxides.
    Bioorganic & medicinal chemistry letters, 2018, 01-15, Volume: 28, Issue:2

    Topics: Administration, Oral; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Mice; Molecular Structure; Nitroimidazoles; Small Molecule Libraries; Structure-Activity Relationship; Trypanosomiasis, African

2018
Novel Pyrimidines as Antitubercular Agents.
    Antimicrobial agents and chemotherapy, 2018, Volume: 62, Issue:3

    Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Design; Drug Stability; Female; Humans; Mice; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Pyrimidines; Solubility; Structure-Activity Relationship; Tuberculosis

2018
Drug-Drug Interactions Between PA-824 and Darunavir Based on Pharmacokinetics in Rats by LC-MS-MS.
    Journal of chromatographic science, 2018, Apr-01, Volume: 56, Issue:4

    Topics: Animals; Chromatography, Liquid; Darunavir; Drug Interactions; Linear Models; Nitroimidazoles; Rats; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry

2018
Antimicrobial activity against Mycobacterium tuberculosis under in vitro lipid-rich dormancy conditions.
    Journal of medical microbiology, 2018, Volume: 67, Issue:3

    Topics: Amikacin; Anti-Bacterial Agents; Antitubercular Agents; Drug Tolerance; Fluoroquinolones; Genetic Fitness; Genotype; Humans; Lipid Metabolism; Lipids; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Mycobacterium tuberculosis; Nitroimidazoles; Rifampin

2018
Untargeted metabolomics reveals a new mode of action of pretomanid (PA-824).
    Scientific reports, 2018, 03-23, Volume: 8, Issue:1

    Topics: Antitubercular Agents; Gas Chromatography-Mass Spectrometry; Humans; Metabolic Networks and Pathways; Metabolome; Metabolomics; Mycobacterium Infections, Nontuberculous; Mycobacterium smegmatis; Nitroimidazoles

2018
Modeling and Simulation of Pretomanid Pharmacokinetics in Pulmonary Tuberculosis Patients.
    Antimicrobial agents and chemotherapy, 2018, Volume: 62, Issue:7

    Topics: Adolescent; Adult; Antitubercular Agents; Female; Humans; Male; Middle Aged; Models, Theoretical; Monte Carlo Method; Nitroimidazoles; Tuberculosis, Pulmonary; Young Adult

2018
Enhanced brain penetration of pretomanid by intranasal administration of an oil-in-water nanoemulsion.
    Nanomedicine (London, England), 2018, Volume: 13, Issue:9

    Topics: Administration, Intranasal; Animals; Brain; Chromatography, Liquid; Drug Delivery Systems; Emulsions; Male; Nanoparticles; Nitroimidazoles; Rats; Rats, Sprague-Dawley; Solid Phase Extraction; Tuberculosis, Meningeal

2018
Coenzyme F
    Journal of bacteriology, 2018, 12-01, Volume: 200, Issue:23

    Topics: Antitubercular Agents; Bacterial Proteins; Drug Resistance, Bacterial; Glucosephosphate Dehydrogenase; Ligases; Methanobacteriaceae; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Polyglutamic Acid; Recombinant Proteins; Riboflavin; Tetrahydrofolates

2018
3D QSAR, Docking, Molecular Dynamics Simulations and MM-GBSA studies of Extended Side Chain of the Antitubercular Drug (6S) 2-Nitro-6- {[4-(trifluoromethoxy) benzyl] oxy}-6,7-dihydro-5H-imidazo[2,1-b] [1,3] oxazine.
    Infectious disorders drug targets, 2019, Volume: 19, Issue:2

    Topics: Antitubercular Agents; Drug Development; Molecular Docking Simulation; Molecular Dynamics Simulation; Nitroimidazoles; Quantitative Structure-Activity Relationship

2019
Rational design of coumarin derivatives as antituberculosis agents.
    Future medicinal chemistry, 2018, Volume: 10, Issue:20

    Topics: Antitubercular Agents; Cell Survival; Coumarins; Drug Design; HeLa Cells; Humans; MCF-7 Cells; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Nitroimidazoles; Signal Transduction; Structure-Activity Relationship; THP-1 Cells

2018
Effect of Moxifloxacin plus Pretomanid against
    Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:1

    Topics: Antitubercular Agents; Drug Combinations; Drug Interactions; Drug Resistance, Fungal; Microbial Sensitivity Tests; Models, Statistical; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles

2019
Design, Synthesis, and Biological Evaluation of 2-Nitroimidazopyrazin-one/-es with Antitubercular and Antiparasitic Activity.
    Journal of medicinal chemistry, 2018, 12-27, Volume: 61, Issue:24

    Topics: Animals; Antiparasitic Agents; Antitubercular Agents; Caco-2 Cells; Drug Design; Drug Evaluation, Preclinical; Drug Stability; Entamoeba histolytica; Giardia lamblia; Humans; Mice; Microbial Sensitivity Tests; Microsomes, Liver; Nitroimidazoles; Structure-Activity Relationship

2018
Comparison of in vitro activity of the nitroimidazoles delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis.
    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2019, Volume: 38, Issue:7

    Topics: Antitubercular Agents; Bacterial Proteins; Drug Resistance, Multiple, Bacterial; Extensively Drug-Resistant Tuberculosis; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Nitroimidazoles; Tuberculosis, Multidrug-Resistant

2019
The Combination Rifampin-Nitazoxanide, but Not Rifampin-Isoniazid-Pyrazinamide-Ethambutol, Kills Dormant Mycobacterium tuberculosis in Hypoxia at Neutral pH.
    Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:7

    Topics: Antitubercular Agents; Drug Combinations; Drug Therapy, Combination; Ethambutol; Humans; Hydrogen-Ion Concentration; Hypoxia; Isoniazid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazolidinones; Pyrazinamide; Rifampin; Tuberculosis

2019
Chalcogen OCF
    ChemMedChem, 2019, 09-04, Volume: 14, Issue:17

    Topics: Animals; Dogs; Humans; Hydrophobic and Hydrophilic Interactions; Madin Darby Canine Kidney Cells; Microsomes, Liver; Molecular Structure; Nitroimidazoles; Organoselenium Compounds; Riluzole; Sulfides

2019
Transcriptional profiling of a laboratory and clinical Mycobacterium tuberculosis strain suggests respiratory poisoning upon exposure to delamanid.
    Tuberculosis (Edinburgh, Scotland), 2019, Volume: 117

    Topics: Aerobiosis; Antitubercular Agents; Cell Wall; Gene Expression Profiling; Gene Expression Regulation, Bacterial; Genome; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; RNA, Bacterial; Sequence Analysis, RNA

2019
Population Pharmacokinetics of the Antituberculosis Agent Pretomanid.
    Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:10

    Topics: Antitubercular Agents; Biological Availability; Clinical Trials as Topic; Extensively Drug-Resistant Tuberculosis; Female; HIV Infections; Humans; Lopinavir; Male; Nitroimidazoles; Rifampin; Ritonavir; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary

2019
Estimating the impact of a novel drug regimen for treatment of tuberculosis: a modeling analysis of projected patient outcomes and epidemiological considerations.
    BMC infectious diseases, 2019, Sep-09, Volume: 19, Issue:1

    Topics: Adult; Antitubercular Agents; Diarylquinolines; Humans; Markov Chains; Nitroimidazoles; Prevalence; Pyrazinamide; Rifampin; South Africa; Treatment Outcome; Tuberculosis; Tuberculosis, Multidrug-Resistant

2019
BPaL approved for multidrug-resistant tuberculosis.
    The Lancet. Infectious diseases, 2019, Volume: 19, Issue:10

    Topics: Antitubercular Agents; Diarylquinolines; Drug Approval; Drug Therapy, Combination; Humans; Linezolid; Mycobacterium tuberculosis; Nitroimidazoles; Tuberculosis, Multidrug-Resistant

2019
Breakthrough in the treatment of drug-resistant tuberculosis.
    The Lancet. Respiratory medicine, 2019, Volume: 7, Issue:12

    Topics: Antitubercular Agents; Humans; Nitroimidazoles; Tuberculosis, Multidrug-Resistant

2019
Duration of pretomanid/moxifloxacin/pyrazinamide therapy compared with standard therapy based on time-to-extinction mathematics.
    The Journal of antimicrobial chemotherapy, 2020, 02-01, Volume: 75, Issue:2

    Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; Mathematics; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Tuberculosis

2020
Are pretomanid-containing regimens for tuberculosis a victory or a victory narrative?
    The Lancet. Respiratory medicine, 2019, Volume: 7, Issue:12

    Topics: Diarylquinolines; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary

2019
Pharmacophore modeling of pretomanid (PA-824) derivatives for antitubercular potency against replicating and non-replicating
    Journal of biomolecular structure & dynamics, 2021, Volume: 39, Issue:3

    Topics: Antitubercular Agents; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Tuberculosis, Multidrug-Resistant

2021
Predicting nitroimidazole antibiotic resistance mutations in Mycobacterium tuberculosis with protein engineering.
    PLoS pathogens, 2020, Volume: 16, Issue:2

    Topics: Antitubercular Agents; Bacterial Proteins; Drug Resistance, Bacterial; Mutation; Mycobacterium tuberculosis; Nitroimidazoles; Nitroreductases; Oxazoles; Polymorphism, Genetic; Protein Engineering

2020
Tuberculosis treatment: one-shot approach or cascade of regimens?
    The Lancet. Respiratory medicine, 2020, Volume: 8, Issue:2

    Topics: Diarylquinolines; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary

2020
Preserved Efficacy and Reduced Toxicity with Intermittent Linezolid Dosing in Combination with Bedaquiline and Pretomanid in a Murine Tuberculosis Model.
    Antimicrobial agents and chemotherapy, 2020, 09-21, Volume: 64, Issue:10

    Topics: Animals; Antitubercular Agents; Diarylquinolines; Linezolid; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Nitroimidazoles; Tuberculosis; Tuberculosis, Multidrug-Resistant

2020
New drugs 2020, part 3.
    Nursing, 2020, Volume: 50, Issue:10

    Topics: Aminophenols; Antibodies, Monoclonal, Humanized; Azabicyclo Compounds; Benzodioxoles; beta-Cyclodextrins; Cilastatin; Drug Approval; Drug Combinations; Ethinyl Estradiol; Genetic Vectors; Humans; Imipenem; Indoles; Nitroimidazoles; Pregnanolone; Pregnenediones; Pyrazoles; Pyridines; Pyrrolidines; Quinolones; Retinoids; United States; United States Food and Drug Administration

2020
Mutations in
    Antimicrobial agents and chemotherapy, 2020, 12-16, Volume: 65, Issue:1

    Topics: Animals; Antitubercular Agents; Mice; Mutation; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles

2020
An Exposure-Response Perspective on the Clinical Dose of Pretomanid.
    Antimicrobial agents and chemotherapy, 2020, 12-16, Volume: 65, Issue:1

    Topics: Antitubercular Agents; Humans; Nitroimidazoles; Retrospective Studies; Tuberculosis, Multidrug-Resistant

2020
Pretomanid for the treatment of pulmonary tuberculosis.
    Drugs of today (Barcelona, Spain : 1998), 2020, Volume: 56, Issue:10

    Topics: Adult; Antitubercular Agents; Humans; Nitroimidazoles; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary

2020
A validated liquid chromatography tandem mass spectrometry assay for the analysis of pretomanid in plasma samples from pulmonary tuberculosis patients.
    Journal of pharmaceutical and biomedical analysis, 2021, Feb-20, Volume: 195

    Topics: Adult; Chromatography, High Pressure Liquid; Chromatography, Liquid; Humans; Nitroimidazoles; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Tuberculosis, Pulmonary

2021
FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs.
    Clinical pharmacology and therapeutics, 2021, Volume: 109, Issue:4

    Topics: Administration, Inhalation; Amikacin; Anti-Bacterial Agents; Antifungal Agents; Cross Infection; Drug Approval; Drug Resistance, Microbial; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Humans; Liposomes; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Nitroimidazoles; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Sisomicin; United States; United States Food and Drug Administration

2021
Mesoporous Silica Nanoparticles Improve Oral Delivery of Antitubercular Bicyclic Nitroimidazoles.
    ACS biomaterials science & engineering, 2022, Oct-10, Volume: 8, Issue:10

    Topics: Amines; Animals; Antitubercular Agents; Drug Carriers; Mice; Nanoparticles; Nitroimidazoles; Organophosphonates; Silicon Dioxide

2022
Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid.
    Scientific reports, 2021, 09-30, Volume: 11, Issue:1

    Topics: Antitubercular Agents; Diarylquinolines; Drug Resistance, Multiple, Bacterial; Humans; Mutation; Mycobacterium smegmatis; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant; Whole Genome Sequencing

2021
    Antimicrobial agents and chemotherapy, 2022, 01-18, Volume: 66, Issue:1

    Topics: Humans; Mycobacterium Infections, Nontuberculous; Nitroimidazoles; Nontuberculous Mycobacteria

2022
Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines.
    BMJ open, 2021, 12-03, Volume: 11, Issue:12

    Topics: Antitubercular Agents; Cost-Benefit Analysis; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Georgia; Humans; Linezolid; Nitroimidazoles; Philippines; South Africa; Tuberculosis, Multidrug-Resistant

2021
Sterile tuberculous granuloma in a patient with XDR-TB treated with bedaquiline, pretomanid and linezolid.
    BMJ case reports, 2021, Dec-07, Volume: 14, Issue:12

    Topics: Antitubercular Agents; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Granuloma; Humans; Linezolid; Nitroimidazoles; Treatment Outcome; Tuberculosis, Multidrug-Resistant

2021
Evaluating the effect of clofazimine against Mycobacterium tuberculosis given alone or in combination with pretomanid, bedaquiline or linezolid.
    International journal of antimicrobial agents, 2022, Volume: 59, Issue:2

    Topics: Antitubercular Agents; Clofazimine; Diarylquinolines; Humans; Linezolid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Tuberculosis, Multidrug-Resistant

2022
Budgetary impact of using BPaL for treating extensively drug-resistant tuberculosis.
    BMJ global health, 2022, Volume: 7, Issue:1

    Topics: Antitubercular Agents; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Humans; Linezolid; Nitroimidazoles

2022
Delamanid or pretomanid? A Solomonic judgement!
    The Journal of antimicrobial chemotherapy, 2022, 03-31, Volume: 77, Issue:4

    Topics: Antitubercular Agents; Diarylquinolines; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant

2022
Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid.
    The Journal of antimicrobial chemotherapy, 2022, 05-29, Volume: 77, Issue:6

    Topics: Antitubercular Agents; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Tuberculosis

2022
Molecular dynamic assisted investigation on impact of mutations in deazaflavin dependent nitroreductase against pretomanid: a computational study.
    Journal of biomolecular structure & dynamics, 2023, Volume: 41, Issue:10

    Topics: Antitubercular Agents; Ligands; Molecular Dynamics Simulation; Mutation; Mycobacterium tuberculosis; Nitroimidazoles; Nitroreductases

2023
Male reproductive hormones in patients treated with pretomanid.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2022, 06-01, Volume: 26, Issue:6

    Topics: Follicle Stimulating Hormone; Humans; Luteinizing Hormone; Male; Nitroimidazoles; Testosterone; Tuberculosis, Multidrug-Resistant

2022
Evidence of safety for pretomanid and male reproductive health.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2022, 06-01, Volume: 26, Issue:6

    Topics: Antitubercular Agents; Humans; Male; Nitroimidazoles; Reproductive Health

2022
Pretomanid in the Treatment of Patients with Tuberculosis in the United States.
    The New England journal of medicine, 2022, 09-01, Volume: 387, Issue:9

    Topics: Antitubercular Agents; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Tuberculosis; Tuberculosis, Multidrug-Resistant; United States

2022
Development and validation of stability-indicating -HPLC method for the determination of related substances in novel nitroimidazole antituberculosis drug pretomanid: Robustness study by Design-Expert and application to stability studies.
    Biomedical chromatography : BMC, 2022, Volume: 36, Issue:12

    Topics: Antitubercular Agents; Chromatography, High Pressure Liquid; Drug Stability; Humans; Nitroimidazoles; Reproducibility of Results

2022
Pharmacodynamics and Bactericidal Activity of Combination Regimens in Pulmonary Tuberculosis: Application to Bedaquiline-Pretomanid-Pyrazinamide.
    Antimicrobial agents and chemotherapy, 2022, 12-20, Volume: 66, Issue:12

    Topics: Antitubercular Agents; Diarylquinolines; Humans; Nitroimidazoles; Pyrazinamide; Tuberculosis; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary

2022
The
    Antimicrobial agents and chemotherapy, 2022, 12-20, Volume: 66, Issue:12

    Topics: Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Nitroimidazoles; Tuberculosis, Multidrug-Resistant

2022
Dynamic
    Nature communications, 2022, 12-29, Volume: 13, Issue:1

    Topics: Animals; Antitubercular Agents; Diarylquinolines; Disease Models, Animal; Humans; Linezolid; Mice; Mycobacterium tuberculosis; Nitroimidazoles; Rabbits; Tuberculosis, Meningeal; Tuberculosis, Multidrug-Resistant

2022
Promise and Peril of Pretomanid-Rifamycin Regimens for Drug-susceptible Tuberculosis.
    American journal of respiratory and critical care medicine, 2023, 04-01, Volume: 207, Issue:7

    Topics: Antitubercular Agents; Humans; Nitroimidazoles; Rifamycins; Tuberculosis

2023
Pretomanid-resistant tuberculosis.
    The Journal of infection, 2023, Volume: 86, Issue:5

    Topics: Antitubercular Agents; Humans; Nitroimidazoles; Tuberculosis; Tuberculosis, Multidrug-Resistant

2023
Predictions of Bedaquiline and Pretomanid Target Attainment in Lung Lesions of Tuberculosis Patients using Translational Minimal Physiologically Based Pharmacokinetic Modeling.
    Clinical pharmacokinetics, 2023, Volume: 62, Issue:3

    Topics: Animals; Antitubercular Agents; Humans; Lung; Mice; Nitroimidazoles; Pyrazinamide; Tuberculosis

2023
Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model.
    Antimicrobial agents and chemotherapy, 2023, 04-18, Volume: 67, Issue:4

    Topics: Animals; Antitubercular Agents; Diarylquinolines; Linezolid; Mice; Nitroimidazoles; Oxazolidinones; Tuberculosis; Tuberculosis, Multidrug-Resistant

2023
DprE2 is a molecular target of the anti-tubercular nitroimidazole compounds pretomanid and delamanid.
    Nature communications, 2023, 06-28, Volume: 14, Issue:1

    Topics: Alcohol Oxidoreductases; Antitubercular Agents; Cell Wall; Drug Resistance; Kinetics; Molecular Targeted Therapy; Mycobacterium tuberculosis; NAD; Nitroimidazoles; Prodrugs; Spectrophotometry

2023
Discovery and characterization of antimycobacterial nitro-containing compounds with distinct mechanisms of action and
    Antimicrobial agents and chemotherapy, 2023, 09-19, Volume: 67, Issue:9

    Topics: Animals; Bacterial Load; Mice; Nitro Compounds; Nitrofurans; Nitroimidazoles

2023
The Implementation of a Pretomanid-Based Treatment Regimen for Multidrug-Resistant Tuberculosis: A Case Series.
    Deutsches Arzteblatt international, 2023, 09-22, Volume: 120, Issue:38

    Topics: Antitubercular Agents; Humans; Nitroimidazoles; Tuberculosis, Multidrug-Resistant

2023